

# Ensuring Effective Antibiotics in the 21<sup>st</sup> Century



# Leading causes of mortality in low-income countries, 2004



## Leading infectious causes of death in low-income countries 2005 (estimates)





### Antimicrobial resistance: bacterial, viral, and parasitic infections, 2009






#### **HIV/AIDS**





Source: WHO


## Proportion of tuberculosis cases with first-line drug resistance, UK, 2000-2008



Source: HPA, UK


#### Percent MDR TB among new cases 1994-2007

\* Sub-national coverage in India, China, Russia, Indonesia.




Source: WHO, 4th global TB report

### Rates of resistance in hospital intensive care units worldwide




Source: Vincent JL et al *JAMA*302(21):2323-2329.

## MRSA and VSRE as percentage of all bacteria isolated from intensive care units, 2007




## Positive blood culture and deaths, neonates with suspected sepsis, Mwanza- Tanzania



Source: Kayange M, et al. Pediatrics 10: 39.

## Use of second and third generation antimicrobials and cost, 2004 estimates




Source: WHO /MHS 2004 International Drug Price Indicator Guide

# "Misuse of drugs could result in selection of resistance" Alexander Fleming, 1945


1928	Penicillin discovered					
1942	Penicillin introduced			_		
1945	Fleming warns of possible resistar	nce				
1946	14% hospital strains resistant					
1950	59% hospital strains resistant					
1960s-70s	Resistance spreads in communitie	s				
1980s-90s	Resistance exceeds 80% in comm	unities,	95% in	most ho	spitals	

### Interval between start of antibiotic use and first report of resistance



Source: Jacoby, G. A. (2009). History of Drug-Resistant Microbe. Antimicrobial Drug Resistance. D. L. Mayers, Humana Press: 3-7. Bergstrom CT, Feldgarden M (2008). The ecology and evolution of antibiotic-resistant bacteria. In Evolution in Health and Disease. 2nd edition. Oxford University Press; 2008.


### Per capita total antibiotic sales, 2005-2010




Source: IMS Health Incorporated.: marketing research

#### Antimicrobial over-use: medical workers

Antibiotic use for common cold, United States, 1997-2002




## Antibiotic use: outpatient penicillin usage correlated with penicillin resistance, Europe, 2005




Source: Goossens, 2005

## Antibiotic over-use: lack of simple diagnostics for human infections




Source: WHO 1997

#### Penicillin resistant Gonorrhoea, 1990s



Source: WHO from published reports

#### Counterfeit Artesunate (53% of all sampled), Southeast Asia, 2006-2007




- (A) Genuine
- (B) Sticker copy
- (C) Fake stamp (only visible under UV light)
- (D) Hologram copy



Source: Newton PN,, et al. (2008). PLoS Med 5(2): 32:10.1371

## P. falciparum parasitaemia 3 day post treatment, artemisinin-based combination therapies (2006-2010)




Source: WHO/Roll Back Malaria Partnership

### Antimicrobial use: mis-understanding by patients


Malaira, chemoprophylaxis, 635 pregnant women, Malawi

% with urine CQ metabolites compatible with intake preceding 7 days




Source: CDC

## Hand hygiene and hospital acquired infections, Australia, 2007



Source: Australia Clinical Excellence Commission, 2007

### Antibiotic consumption in animals, 2005









**Source: Agbioforum** 

#### Antibiotic use: use in plants, fish and animals

US: OVER-USE OF ANTIBIOTICS THREATENS HUMANS by Danielle Knight

Washington, 11 Oct. (IPS) -


More than half of the antibiotics used in the United States are estimated to be used in **animal feed** for poultry, hogs, and cattle In 80 percent of cases, the drugs are used to **fatten the animals faster**.

Between 40,000 and 50,000 pounds of tetracycline and streptomycin - both used to treat infections in humans - are sprayed to control bacterial disease among fruit trees.

In the United States nearly 150 pounds of antibiotic are applied per acre of salmon


**Source: Inter Press Service** 

## Multidrug-resistant Definitive Type (DT) 104 Salmonella Typhimurium, Europe, 1982-1996




Source: WHO from published data

## Failing research and development: 90/10 gap




Source: Global Forum for Health Research

## Discovery of antibiotics: a faltering pipeline




Source: Wright G.. Nature Reviews Microbiology 5, 175-186 (March 2007)

#### Global Spread of Chloroquine-Resistant Strains of *P. falciparum*, 1950-1980




Source: Cell. 1997. Global spread of chloroquine-resistant strains of P. falciparum.

# Spread of multi-resistant pneumococcus first identified in Spain, 1990s




Source: Klugmann, South African Institute of Medical Research

# Carbapenamase-producing Enterobacteriaceae strains. Bangladesh, India, Pakistan and the UK, 2009




Source: Kumarasamy KK, et al Lancet ID, 2010

### WHO Global strategy for containment of resistance, 2001



#### The five key areas for containment of antimicrobial resistance



### Campaign to decrease antibiotic demand, Europe





FIGURE 2

Trends of outpatient antibiotic use (ATC group J01) in 29 European countries, 1998-2005



DDD per 1,000 inhabitants and per day (rows represent the years 1998-2005, top to bottom, with 2005 in darker colour)


\* BG, EL, IS: Total use, i.e. including the hospital sector (EL, only for 2004 and 2005).

\*\* ES: reimbursement data, which do not include over-the-counter sales without a prescription.

## Hospital Acquired Infections and antimicrobial resistance, 1993 - 2005



Annual Hospital Admissions with MRSA USA




Source: CDC, USA

### European ban on use of antibiotic for animal growth promotion



### Antimicrobial use in Salmon and trout production in Norway



Source: FAO/OIE/WHO Expert consultation on antimicrobial use in aquaculture and antimicrobial resistance, 2006

## WHO - Patient Safety Programme Report on examples of containment



#### Patient Safety

A World Alliance for Eafor Health Core



#### COMBATING ANTIMICROBIAL RESISTANCE: EXPERIENCES FROM THE FIELD

A reference book describing the need for and examples of successful interventions

To help national policy-makers dealing with health, the pharmaceutical industry, animal husbandry and civil society engagement, WHO will release, in 2011, a book entitled 'COMBATING ANTIMICROBIAL RESISTANCE: EXPERIENCES FROM THE FIELD'. The book builds and expands on the six points highlighted in the World Health Day 2011 policy package to tackle the growing global problem of antimicrobial resistance. It provides in-depth analysis of the need for and examples of successful interventions in reducing antimicrobial resistance across WHO Member States. It is the result of wide international expert consultations organized by WHO, supported by literature reviews and experiences of groups involved in addressing AMR at the national and international level.

#### The Causes

#### The Problem

#### Possible Solutions

#### SIX MAJOR FACTORS TOGETHER DRIVE AMR: INTERVENTIONS NEED TO ADDRESS ALL THESE FACTORS

Lack of comprehensive national actions with civil society engagement to address AMR

Lack of laboratory capacity and surveillance lead to inadequate information for choosing treatment for individual patient and for making policy decisions

Overuse of antibiotics for diseases that do not require them and underuse due to insufficient doses, duration or use of antibiotics of substandard potency

Unnecessary use of antibiotics in food-producing arimals, especially for supposed benefits in disease prevention and growth promotion

Insufficient measures to prevent the spread of resistant bacteria in hospitals and the community

Inadequate momentum in research and development in the essential technologies to combat AMR, e.g. drug, diagnostics and vaccine BACTERIA DEVELOP RESISTANCE AND RESISTANT BACTERIA THRIVE

SPREAD

PATIENTS AT RISK OF PROLONGED DISEASE, MORE COMPLICATIONS OR NO CURE AT ALL DUE TO DELAY OR ABSENCE OF CORRECT TREATMENT

DIRECT AND INDIRECT COSTS TO PATIENTS AND THEIR FAMILIES

#### COMBATING ANTIMICROBIAL RESISTANCE: EXPERIENCES FROM THE FIELD

Addressing the six points identified for action in the World Health Day 2011 policy package

The evidence for action

Surveillance of antimicrobial resistance and use

Rational drug use and regulations

Animal husbandry regulations

Infection prevention and control in health-care

Enabling innovations in technology

Intersectoral and multi-disciplinary nationally coordinated actions involving civil society

## Antimicrobial resistance: the problem is global, the solutions are local



